Why the study?
The 2023 ESVS guidelines were developed to expand the earlier 2017 guidelines and provide answers to previously unanswered questions regarding the management of atherosclerotic carotid and vertebral artery disease.
The 2023 ESVS guidelines provide updated, comprehensive recommendations for managing carotid and vertebral artery disease, including new guidance on high-risk patients and cognitive decline.
Updates carotid and vertebral disease management; extends prior guidelines with new recommendations for high-risk patients and cognitive outcomes.
The 2023 European Society for Vascular Surgery (ESVS) clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease1 is a comprehensive document that expands considerably the earlier (2017) ESVS Carotid and Vertebral Guidelines.2 The 2023 Guidelines include a total of 133 recommendations, of which 84 remained unchanged, 11 have been regraded since the previous Guidelines,2 and 38 are new.1 Importantly, the new Guidelines provide answers to a number of previously “unanswered questions”, such as which patients are “high risk” for carotid endarterectomy (CEA) or carotid artery stenting (CAS), if there is an association between asymptomatic carotid stenosis (ACS) and cognitive decline, if this can be reversed/prevented by CEA/CAS, as well as other important issues.
No takes yet. Share an insight, caveat, or question.
Zeebregts et al. (2022) conducted a review in atherosclerotic carotid and vertebral artery disease. 2023 ESVS Carotid Guidelines was evaluated. The 2023 ESVS clinical practice guidelines on atherosclerotic carotid and vertebral artery disease provide 133 recommendations, including 38 new recommendations addressing previously unanswered questions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: